Spruce Street Capital LP Raises Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Spruce Street Capital LP increased its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 75.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 761,063 shares of the company’s stock after purchasing an additional 326,081 shares during the period. Kiniksa Pharmaceuticals International accounts for 8.8% of Spruce Street Capital LP’s holdings, making the stock its 2nd biggest holding. Spruce Street Capital LP’s holdings in Kiniksa Pharmaceuticals International were worth $36,645,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its holdings in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new position in shares of Kiniksa Pharmaceuticals International in the second quarter worth $31,000. KBC Group NV bought a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth $34,000. Smartleaf Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth $36,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in Kiniksa Pharmaceuticals International during the fourth quarter valued at $41,000. 53.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on KNSA. Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. The Goldman Sachs Group lifted their target price on Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the stock a “buy” rating in a report on Thursday. Wedbush boosted their target price on Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, June 29th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $68.00.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA opened at $62.84 on Friday. The firm has a market cap of $4.83 billion, a PE ratio of 69.82 and a beta of 0.07. The firm’s 50 day simple moving average is $56.87 and its 200-day simple moving average is $49.97. Kiniksa Pharmaceuticals International, plc has a one year low of $26.27 and a one year high of $67.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The business had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. During the same period in the previous year, the company posted $0.11 EPS. Kiniksa Pharmaceuticals International’s revenue was up 55.5% on a year-over-year basis. Equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, CEO Sanj K. Patel sold 48,565 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the sale, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at $2,623,481.30. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the company’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. This trade represents a 51.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 628,427 shares of company stock worth $32,833,228 over the last three months. 51.98% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.